SOURCE: Biolex Therapeutics

May 03, 2007 09:00 ET

Biolex Therapeutics' LEX System(SM) Featured in Breakout Session at the 2007 BIO International Convention

PITTSBORO, NC -- (MARKET WIRE) -- May 3, 2007 -- Biolex Therapeutics today announced that its LEX System(SM) technology for enabling hard-to-make proteins and optimizing monoclonal antibodies will be featured at the "Prevention and Cure: Contributions of Plant Biotechnology to Human Health" session at the 2007 BIO International Convention. David Spencer, Ph.D., Biolex's Chief Operating Officer and Senior Vice President, Research and Development, will highlight the ability of the Company's LEX System to increase the efficacy and potency of monoclonal antibodies and to enable the development and commercialization of new therapeutic proteins not well expressed in other systems. The session will take place at 4:00 p.m. EDT on Monday, May 7th at the Boston Convention & Exhibition Center in Room 253 B.

Microbial and mammalian cell protein expression systems, the platforms historically used for the production of biologics, have well-understood capabilities and limitations. The Company's LEX System, based on the aquatic plant Lemna, has been demonstrated to be simpler and less expensive to set up and operate in GMP production. The LEX System also enables the commercial production of important new therapeutic proteins, such as full-length recombinant plasmin (BLX-155), that can not be produced at commercially viable levels in existing systems. Furthermore, the LEX System has demonstrated an unprecedented ability to express human monoclonal antibodies with a homogenous glycosylation structure supportive of enhanced potency and efficacy. These capabilities were highlighted in a recent issue of Nature Biotechnology.

"Today, the LEX System is being used by Biolex and its partner companies to leverage the platform's attributes, including simple and efficient production and viral and prion safety, to develop and commercialize hard-to-make proteins and unique glyco-optimized monoclonal antibodies," said David Spencer, Ph.D., Biolex's Chief Operating Officer and Senior Vice President, Research and Development.

About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on the LEX System(SM), its patented expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies. The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex's lead clinical candidate, Locteron™, is being developed as a best-in-class controlled-release interferon alfa for the treatment of hepatitis C and is currently in Phase 2 testing. The Company's second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, deep vein thrombosis and catheter occlusion. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies. Biolex is a venture capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex's web site at www.biolex.com.

Contact Information

  • Contacts:
    Media: Michelle Linn,
    Linnden Communications
    508-419-1555
    Email Contact

    Investors:
    Dale Sander
    Chief Financial Officer
    858-663-6993
    Email Contact